BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 13057308)

  • 1. [The passage of intravenously injected iron from the blood stream].
    OVERKAMP H
    Z Gesamte Exp Med; 1952; 120(1):86-95. PubMed ID: 13057308
    [No Abstract]   [Full Text] [Related]  

  • 2. [The behavior of intravenously administered iron in the organism].
    LINTZEL W
    Arztl Forsch; 1953 Mar; 7(3):I/134-6. PubMed ID: 13065190
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intravenous iron].
    DUFRESNE RR
    Union Med Can; 1952 Jun; 81(6):697-8. PubMed ID: 13005802
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tolerance of intravenous iron application].
    GOLDECK H; REMY D; MEYER F
    Arztl Wochensch; 1952 May; 7(21):489-90. PubMed ID: 14952397
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron in hematology: Danger with IV iron: Real or perceived?
    Auerbach M
    Am J Hematol; 2014 Jun; 89(6):664. PubMed ID: 24639085
    [No Abstract]   [Full Text] [Related]  

  • 6. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.
    Alan Brookhart M; Li X; Kshirsagar AV
    Semin Dial; 2017 Jan; 30(1):25-27. PubMed ID: 27766683
    [No Abstract]   [Full Text] [Related]  

  • 7. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron.
    Wish JB
    Semin Dial; 2017 Jan; 30(1):20-22. PubMed ID: 27679413
    [No Abstract]   [Full Text] [Related]  

  • 8. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.
    Agarwal R
    Semin Dial; 2017 Jan; 30(1):22-25. PubMed ID: 27678472
    [No Abstract]   [Full Text] [Related]  

  • 9. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Role for Newly Approved Iron Treatments.
    Fishbane S
    Semin Dial; 2017 Jan; 30(1):27-29. PubMed ID: 27687015
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous iron therapy in end-stage renal disease.
    Brewster UC
    Semin Dial; 2006; 19(4):285-90. PubMed ID: 16893405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.
    Besarab A; Szczech L
    Semin Dial; 2017 Jan; 30(1):29-31. PubMed ID: 27699882
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intravenous iron therapy].
    Med Contemp; 1952 May; 70(5):299-301. PubMed ID: 14956388
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous iron therapy.
    VARIAVA NS
    Antiseptic; 1952 Mar; 49(3):210-7. PubMed ID: 14934073
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds.
    Toblli JE; Cao G; Olivieri L; Angerosa M
    Nephrol Dial Transplant; 2010 Nov; 25(11):3631-40. PubMed ID: 20488820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experiences with intravenous iron therapy].
    SELIGER H
    Ther Ggw; 1952 Feb; 91(2):55-7. PubMed ID: 14922346
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.
    Daniilidis A; Panteleris N; Vlachaki E; Breymann C; Assimakopoulos E
    J Obstet Gynaecol; 2018 May; 38(4):443-447. PubMed ID: 29057687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma iron levels after the intravenous administration of different iron preparations.
    NISSIM JA
    J Physiol; 1952 Dec; 118(4):63P-64P. PubMed ID: 13023666
    [No Abstract]   [Full Text] [Related]  

  • 19. [Intravenous iron therapy with ferrum injectabile Vitis].
    PRIBILLA W
    Medizinische; 1952 Jun; 2():53-6. PubMed ID: 14940483
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.